Newron Pharmaceuticals (United States)

Recent papers from Newron Pharmaceuticals (United States)

1. Real-world chronic recordings from implantable adaptive deep brain stimulation systems for Parkinson’s disease motor state classificationFrontiers in Bioinformatics · 2026
2. PTPN11-related Noonan syndrome predisposes to multifocal low-grade CNS tumors harboring FGFR1 variantsJournal of Neuro-Oncology · 2026
3. Efficacy and Safety of Evenamide, a glutamate modulator: Results from a Phase 2/3, international, randomized, double-blind, placebo-controlled add-on trialEuropean Psychiatry · 2025
4. Phase 3 program of evenamide, a glutamate release modulator, as add-on in patients with treatment-resistant schizophrenia: design of a potentially pivotal, international, randomized, double-blind, placebo-controlled trialEuropean Psychiatry · 2025
5. Design of a Phase 3, Potentially Pivotal, International, Randomized, Double-Blind, Placebo-Controlled Trial With Evenamide, a Glutamate Modulator, Add-on to Sga in Patients With Treatment-Resistant SchizophreniaThe International Journal of Neuropsychopharmacology · 2025
6. Evenamide, a Glutamate Modulator, Provided Statistically Significant Benefits When Added to Sga in Patients With Schizophrenia: Phase 2/3, International, Randomized, Double-Blind, Placebo-Controlled Study ResultsThe International Journal of Neuropsychopharmacology · 2025
7. Chronic adaptive versus conventional deep brain stimulation in Parkinson’s disease: a blinded randomized pilot trial2025
8. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low‐Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE‐IT Randomized TrialJournal of the American Heart Association · 2025
9. Double-blind cross-over pilot trial protocol to evaluate the safety and preliminary efficacy of long-term adaptive deep brain stimulation in patients with Parkinson’s diseaseBMJ Open · 2022
10. Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH StudyJournal of the American Heart Association · 2021
11. Experimental Therapeutics for Challenging Clinical Care of a Patient with an Extremely Rare Homozygous APOC2 MutationCase Reports in Endocrinology · 2020
12. Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studiesAutism · 2019
13. Pharmacokinetics of eicosapentaenoic acid in plasma and red blood cells after multiple oral dosing with icosapent ethyl in healthy subjectsClinical Pharmacology in Drug Development · 2013
14. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR studyCardiovascular Diabetology · 2013
15. Complement C1q Is Dramatically Up-Regulated in Brain Microglia in Response to Transient Global Cerebral IschemiaThe Journal of Immunology · 2000